Avra Laboratories Private Limited in signing the definitive agreements for the sale of controlling stake to Advent International

EY has successfully advised the shareholders of Avra Laboratories in the sale of controlling stake in the company to Advent International. 

EY acted as the exclusive financial advisor to the shareholders of Avra Laboratories.

Avra Laboratories Private Limited is a research-oriented CRAMS and API manufacturer with a USFDA approved facility, headquartered in Hyderabad, India. Founded by Padma Shri and Padma Bhushan Dr. A V Rama Rao in 1995, Avra has over the years developed numerous novel patented processes for the synthesis of complex molecules creating a niche of its own in the API manufacturing space. The company focuses on custom synthesis of proprietary molecules and process optimisation for global innovator customers. The company manufacturers products across therapeutic areas including Oncology, Ophthalmology and specialty chemicals for the electronics industry.

Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 380 private equity investments across 42 countries, and as of September 30, 2021, had $86 billion in assets under management. Advent has been investing in India since 2007. Currently, it has invested/ committed ~ $2.9 billion in 18 companies with headquarters or operations in the country. The acquisition builds towards Advent’s goal of creating a top 5 merchant API Platform in India.